Cardiovascular responses to adenosine in fetal sheep: autonomic blockade.
The mechanism by which adenosine increases heart rate was investigated in 21 chronically catheterized fetal sheep (> 0.8 term). Intra-arterial infusion of adenosine (0.16 mg.min-1.kg fetal wt-1) for 1 h significantly increased fetal heart rate within 5 min with maximum values of approximately 68 beats/min above the control mean of 163 +/- 8 beats/min. The average diastolic blood pressure was reduced only during the first 10 min of infusion, and the average systolic and mean arterial pressures were not significantly affected. Mean venous pressure rose by approximately 48% after 20 min of adenosine infusion, but all other measurements did not differ significantly from the control value. The mean hemoglobin concentration during the last 30 min of infusion was increased by approximately 8%. Plasma concentrations of norepinephrine and epinephrine were elevated only during the first 30 min of adenosine administration, to values as high as 2.3 and 5 times the respective control mean. Adenosine significantly increased mean fetal heart rate by about 15-20 beats/min in fetuses with autonomic ganglion blockade or combined cholinergic, alpha-, and beta-adrenergic receptor blockade. Intra-arterial infusion of CGS 21680C, an A2-adenosine receptor agonist, also produced a fetal tachycardia of approximately 86 beats/min above the control mean and increased intrinsic fetal heart rate by approximately 38 beats/min. It is concluded that approximately 75% of the positive chronotropic effects of adenosine are produced by A2-receptor stimulation of the autonomic nervous system and that approximately 25% of the rise in heart rate induced by adenosine may be caused by activation of A2-receptors in myocardium.
Koos
B J
BJ
Department of Obstetrics and Gynecology, Nicholas S. Assali Perinatal Research Laboratory, UCLA School of Medicine 90024.
Mason
B A
BA
Ducsay
C A
CA
D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology*; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D001340:Autonomic Nerve Block; D001341:Autonomic Nervous System / Q000196:embryology*; D002319:Cardiovascular System / Q000196:embryology*; D002395:Catecholamines / Q000097:blood; D002628:Chemoreceptor Cells / Q000502:physiology; D004622:Embryo, Mammalian / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005312:Fetal Blood; D006340:Heart Rate, Fetal / Q000187:drug effects; D009407:Nerve Block; D010275:Parasympathetic Nervous System / Q000502:physiology; D010627:Phenethylamines / Q000494:pharmacology; D011247:Pregnancy; D012756:Sheep; D013564:Sympathetic Nervous System / Q000502:physiology
D000316:Adrenergic alpha-Agonists; D002395:Catecholamines; D010627:Phenethylamines; C061282:2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; D000241:Adenosine